Home > NNRTIs & > Nevirapine

Nevirapine

奈韦拉平,奈伟拉平,NSC-641530,NSC641530,NSC 641530

Nevirapine (奈韦拉平) 是非核苷类逆转录酶抑制剂（NNRTI），可与核苷类似物结合用于抗HIV。

目录号
EY0737
EY0737
EY0737
EY0737
纯度
99.52%
99.52%
99.52%
99.52%
规格
5 mg
10 mg
50 mg
100 mg
原价
298
490
980
1450
售价
298
490
980
1450
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Erickson DA, et al. Drug Metab Dispos, 1999, 27(12), 1488-1495.
    [2] Guay, L A., et al., 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 354(9181): 795-802.
    [3] Hargrave, K D., et al., 1991. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. Journal of medicinal chemistry. 34(7): 2231-41.
    [4] Cheeseman, S H., et al., 1993. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrobial agents and chemotherapy. 37(2): 178-82.

    分子式
    C15H14N4O    		 分子量
    266.3    		 CAS号
    129618-40-2    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    55 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00905489 HIV Infections Drug: Nevirapine Immediate Release (IR)|Drug: Nevirapine Extended Release (XR) Boehringer Ingelheim Phase 1 2009-06-01 2015-12-02
    NCT00704249 HIV Infections Drug: nevirapine|Drug: nevirapine Clinical Trial Agency of HIV Study Group Phase 4 2006-07-01 2009-02-10
    NCT00415090 HIV Infections Drug: Nevirapine Hospital de Calella Phase 4 2004-08-01 2008-10-30
    NCT00294892 HIV Infections Drug: carbamazepine and nevirapine|Drug: Nevirapine Radboud University Phase 2 2006-02-01 2012-05-30
    NCT00617643 HIV Infections|Tuberculosis Drug: Nevirapine without dose escalation|Drug: Nevirapine initiation with dose escalation Makerere University|University of Liverpool Phase 4 2008-05-01 2010-12-03
    NCT01805258 HIV/TB Co-infection Drug: Nevirapine|Drug: Efavirenz All India Institute of Medical Sciences, New Delhi|National AIDS Control Organisation Phase 3 2007-06-01 2013-03-25
    NCT02166502 Human Immunodeficiency Virus|HIV|Vertical Infection Transmission The Hospital for Sick Children|Canadian Foundation for AIDS Research (CANFAR)|Children's Hospital of Eastern Ontario|St. Michael's Hospital, Toronto|Mount Sinai Hospital, Canada Phase 3 2012-02-01 2015-11-17
    NCT00144248 HIV Infections|Hepatic Insufficiency Drug: nevirapine Boehringer Ingelheim Phase 4 2004-05-01 2013-11-04
    NCT01335360 HIV Infection Drug: Nevirapine Western University of Health Sciences|Jeffrey Goodman Clinic, LA Gay & Lesbian Center 2003-05-01 2011-04-12
    NCT00310843 HIV Infections Drug: Nevirapine Boehringer Ingelheim Phase 4 2006-02-01 2013-07-31
    NCT00273988 Acquired Immunodeficiency Syndrome Drug: nevirapine Boehringer Ingelheim Phase 4 2002-04-01 2013-10-30
    NCT00483054 HIV Infections|Tuberculosis Drug: efavirenz|Drug: nevirapine Bamrasnaradura Infectious Diseases Institute|Mahidol University|Chulalongkorn University Phase 3 2007-01-01 2011-11-21
    NCT02191189 Healthy Drug: Nevirapine suspension, into Enterion鈩?capsule|Drug: Nevirapine suspension Boehringer Ingelheim Phase 1 2005-05-01 2014-07-15
    NCT01277627 HCV Infection.|HCV Viral Load. Drug: Nevirapine|Drug: efavirenz, protease inhibitors Valme University Hospital|Boehringer Ingelheim 2011-01-01 2011-01-14
    NCT02184299 HIV Infections Drug: Nevirapine|Drug: Prednisone Boehringer Ingelheim Phase 4 1999-04-01 2014-07-11
    NCT00986063 Nevirapine Induced Rash|Nevirapine Induced Hepatitis|HIV|Adverse Side Effects|AIDS|HIV Infections Genetic: Genetic test for NVP induced rash|Other: 3TC/D4T/NVP or 3TC/AZT/NVP Surakameth Mahasirimongkol|Mahidol University|Chulalongkorn University|Thammasat University|Srinakharinwirot University|National Institutes of Health (NIH)|RIKEN Phase 4 2009-07-01 2013-04-19
    NCT02184091 Renal Insufficiency|Hepatic Insufficiency Drug: Nevirapine Boehringer Ingelheim Phase 1 1999-01-01 2014-07-11
    NCT00061321 HIV Infections Drug: Nevirapine and mulitvitamins National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 2002-08-01 2008-07-30
    NCT00074399 HIV Infections Drug: Nevirapine|Drug: Nevirapine placebo National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 2001-02-01 2009-08-06
    NCT00620438 HIV Infections|Tuberculosis Drug: Lumefantrine-artemether and nevirapine|Drug: lumefantrine-artemether and efavirenz|Drug: Lumefantrine-artemether and rifampicin Makerere University|Health Research Board, Ireland Phase 4 2008-02-01 2010-12-03

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：